PDF icon PDF herunterladen
Aktuelle Urol 2003; 34(5): 319-327
DOI: 10.1055/s-2003-42008
Übersichtsarbeit
© Georg Thieme Verlag Stuttgart · New York

Perioperative Immunmodulation beim Nierenzellkarzinom - eine Standortbestimmung

Perioperative Immune Modulation in Renal Cell Carcinoma - Review of the Current SituationM.  Böhm1 , T.  Klatte1 , E.  P.  Allhoff1
  • 1Urologische Klinik, Otto-von-Guericke Universität, Leipziger Str. 44, 39120 Magdeburg
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
11. September 2003 (online)

Auch verfügbar aufeRef
   Lizenzen und Reprints
Preview

Zusammenfassung

Die wesentlichen Therapieoptionen beim Nierenzellkarzinom sind Chirurgie und Immuntherapie. Die Chirurgie geht allerdings mit einer erheblichen perioperativen Immundysfunktion einher. Diese Immundysfunktion kann durch eine Vorbehandlung mit Interleukin-2 (IL-2) moduliert werden, was das tumorspezifische Überleben zu verbessern scheint. Die perioperative Immunmodulation könnte die therapeutische Lücke zwischen neoadjuvanter und adjuvanter Immuntherapie schließen. In diesem Artikel wird die verfügbare Literatur kritisch gesichtet und eigene Originaldaten an 63 Patienten präsentiert.

Abstract

Surgery and immunotherapy are the mainstay in the treatment of renal cell carcinoma. Surgery, however, is associated with considerable perioperative immunodysfunction. This immunodysfunction can be modulated by pretreatment with Interleukin-2 (IL-2), which appears to prolong tumour-specific survival. Perioperative immunomodulation could help close the therapeutic gap between neoadjuvant and adjuvant immunotherapy. This article reviews recent literature and presents original data of 63 patients.

Schlüsselwörter

Immunmodulation - perioperativ - Interleukin-2 - Nierentumor

Key words

Immunomodulation - perioperative - interleukin-2 - renal cancer

Literatur

  • 1 Hermanek P, Schrott K M. Evaluation of the new tumor, nodes and metastasis classification of renal cell carcinoma.  J Urol. 1990;  144 238-242
    PubMedSuche in Google Scholar
  • 2 Carl P, Klein U, Gebauer A, Schmiedt E. The value of lymphography for the TNM classification of renal carcinoma.  Eur Urol. 1977;  3 286-288
    PubMedSuche in Google Scholar
  • 3 Giuliani L, Giberti C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors.  J Urol. 1990;  143 468-474
    PubMedSuche in Google Scholar
  • 4 Sánchez de la Muela P, Zudaire J J, Robles J E, Rosell D, Aguera L, De Castro F, Isa W, Berián J M. Renal cell carcinoma: vena caval invasion and prognostic factors.  Eur Urol. 1991;  19 284-290
    PubMedSuche in Google Scholar
  • 5 Herrlinger A, Schrott K M, Schott G, Sigel A. What are the benefits of extended dissection of the regional lymph nodes in the therapy of renal cell carcinoma?.  J Urol. 1991;  146 1224-1227
    PubMedSuche in Google Scholar
  • 6 Eschwege P, Saussine C, Steichen G, Delepaul B, Drelon L, Jacqmin D. Radical nephrectomy for renal cell carcinoma 30 mm or less: long-term follow results.  J Urol. 1996;  155 1196-1199
    PubMedSuche in Google Scholar
  • 7 Takashi M, Takagi Y, Sakata T, Shimoji T, Miyake K. Clinicopathological characteristics of small renal cell carcinomas.  Int Urol Nephrol. 1994;  26 621-629
    PubMedSuche in Google Scholar
  • 8 Siminovitch J P, Montie J E, Straffon R A. Lymphadenectomy in renal adenocarcinoma.  J Urol. 1982;  127 1090-1091
    PubMedSuche in Google Scholar
  • 9 Hultén L, Rosencrantz M, Seeman T, Wahlqvist L, Åhrén C. Occurrence and localization of lymph node metastases in renal carcinoma.  Scand J Urol Nephrol. 1969;  3 129-133
    PubMedSuche in Google Scholar
  • 10 Robson C J, Churchill B M, Anderson W. The results of radical nephrectomy for renal cell carcinoma.  J Urol. 1969;  101 297-301
    PubMedSuche in Google Scholar
  • 11 Parry-Billings M, Baigrie R J, Lamont P M, Morris P J, Newsholme E A. Effects of major and minor surgery on plasma glutamine and cytokine levels.  Arch Surg. 1992;  127 1237-1240
    PubMedSuche in Google Scholar
  • 12 Hensler T, Hecker H, Heeg K, Heidecke C-D, Bartels H, Barthlen W, Wagner H, Siewert J R, Holzmann B. Distinct mechanisms of immunosuppression as a consequence of major surgery.  Infect Immun. 1997;  65 2283-2291
    PubMedSuche in Google Scholar
  • 13 Allendorf J D, Bessler M, Whelan R L, Trokel M, Laird D A, Terry M B, Treat M R. Postoperative immune function varies inversely with the degree of surgical trauma in a murine model.  Surg Endosc. 1997;  11 427-430
    CrossrefPubMedSuche in Google Scholar
  • 14 Kuntz C, Wunsch A, Bay F, Windeler J, Glaser F, Herfarth C. Prospective randomized study of stress and immune response after laparoscopic vs. conventional colonic resection.  Surg Endosc. 1998;  12 963-967
    CrossrefPubMedSuche in Google Scholar
  • 15 Gitzelmann C A, Mendoza-Sagaon M, Talamini M A, Ahmad S A, Pegoli W J, Paidas C N. Cell-mediated immune response is better preserved by laparoscopy than laparotomy.  Surgery. 2000;  127 65-71
    CrossrefPubMedSuche in Google Scholar
  • 16 Ogawa K, Hirai M, Katsube T, Murayama M, Hamaguchi K, Shimakawa T, Naritake Y, Hosokawa T, Kajiwara T. Suppression of cellular immunity by surgical stress.  Surgery. 2000;  127 329-336
    CrossrefPubMedSuche in Google Scholar
  • 17 Leaver H A, Craig S R, Yap P L, Walker W S. Lymphocyte responses following open and minimally invasive thoracic surgery.  Eur J Clin Invest. 2000;  30 230-238
    CrossrefPubMedSuche in Google Scholar
  • 18 Böhm M, Ittenson A, Philipp C, Röhl F-W, Ansorge S, Allhoff E P. Complex perioperative immunodysfunction in patients with renal cell carcinoma.  J Urol. 2001;  166 831-836
    PubMedSuche in Google Scholar
  • 19 Ashida S, Okuda H, Chikazawa M, Tanimura M, Sugita O, Yamamoto Y, Nakamura S, Moriyama M, Shuin T. Detection of circulating cancer cells with von Hippel-Lindau gene mutation in peripheral blood of patients with renal cell carcinoma.  Clin Cancer Res. 2000;  6 3817-3822
    PubMedSuche in Google Scholar
  • 20 McKiernan J M, Buttyan R, Bander N H, de-la-Taille A, Stifelman M D, Emanuel E R, Bagiella E, Rubin M A, Katz A E, Olsson C A, Sawczuk I S. The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9.  Cancer. 1999;  86 492-497
    CrossrefPubMedSuche in Google Scholar
  • 21 Bilkenroth U, Taubert H, Riemann D, Rebmann U, Heynemann H, Meye A. Detection and enrichment of disseminated renal carcinoma cells from peripheral blood by immunogenetic cell separation.  Int J Cancer. 2001;  92 577-582
    CrossrefPubMedSuche in Google Scholar
  • 22 Thèze J. The cytokine network and immune functions. New York: Oxford University Press 1999
    Suche in Google Scholar
  • 23 Mocellin S, Wang E, Marincola F M. Cytokines and immune response in the tumor microenvironment.  J Immunther. 2001;  24 392-407
    PubMedSuche in Google Scholar
  • 24 Abbas A K, Lichtman A H, Pober J S. Cellular and molecular immunology. Philadelphia: Saunders 2000
    Suche in Google Scholar
  • 25 Smith K A. IL-2. In: Oppenheim JJ, Feldman M (Hrsg.). Cytokine reference. London: Academic Press 2001: 113-126
    Suche in Google Scholar
  • 26 Civallero M, Barni S, Nano R, Capelli E. Dendritic cells and interleukin-2: cytochemical and ultrastructural study.  Histol Histopathol. 2000;  15 1077-1085
    PubMedSuche in Google Scholar
  • 27 Schnurr M, Galambos P, Scholz C, Dauer M, Krug A, Hartmann G, Eigler A, Endres S. Deutsches Ärzteblatt . 2002;  99 A2408-A2416
    PubMedSuche in Google Scholar
  • 28 Overwijk W W, Theoret M R, Restifo N P. The future of Interleukin-2: enhancing therapeutic anticancer vaccines.  Cancer J Sci AM. 2000;  6 Suppl 1 S76-S80
    PubMedSuche in Google Scholar
  • 29 Hoffman D M, Figlin R A. Intratumoral interleukin-2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex.  World J Urol. 2000;  18 152-156
    CrossrefPubMedSuche in Google Scholar
  • 30 Larchian W A, Horiguchi Y, Nair S K, Fair W R, Heston W D, Gilboa E. Effectiveness of combined Interleukin-2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer.  Clin Cancer Res. 2000;  6 2913-2920
    PubMedSuche in Google Scholar
  • 31 Dudley M E, Wunderlich J R, Robbins P F, Yang J C, Hwu P, Schwartzentruber D J, Topalian S L, Sherry R, Restifo N P, Hubicki A M, Robinson M R, Raffeld M, Duray P, Seipp C A, Rogers-Freezer L, Morton K E, Mavroukakis S A, White D E, Rosenberg S A. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes.  Science. 2002;  298 850-854
    CrossrefPubMedSuche in Google Scholar
  • 32 Holden S A, Lan Y, Pardo A M, Wesolowski J S, Gillies S D. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.  Clin Cancer Res. 2001;  7 2862-2869
    PubMedSuche in Google Scholar
  • 33 Nichols P H, Ramsden C W, Ward U, Sedman P C, Primrose J N. Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer.  Cancer Res. 1992;  52 5765-5769
    PubMedSuche in Google Scholar
  • 34 Nichols P H, Ramsden C W, Ward U, Trejdosiewicz L K, Ambrose N S, Primrose J N. Perioperative modulation of cellular immunity in patients with colorectal cancer.  Clin Exp Immunol. 1993;  94 4-10
    PubMedSuche in Google Scholar
  • 35 Deehan D J, Heys S D, Simpson W, Broom J, McMillan D N, Eremin O. Modulation of the cytokine and acute-phase response to major surgery by recombinant interleukin-2.  Br J Surg. 1995;  82 86-90
    PubMedSuche in Google Scholar
  • 36 Böhm M, Ittenson A, Schierbaum K F, Röhl F-W, Ansorge S, Allhoff E P. Petreatment with interleukin-2 (IL-2) attenuates perioperative immunodysfunction in patients with renal cell carcinoma.  Eur Urol. 2002;  41 458-468
    CrossrefPubMedSuche in Google Scholar
  • 37 Brivio F, Lissoni P, Alderi G, Barni S, Lavorato F, Fumagalli L. Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advances colorectal cancer patients.  Oncology. 1996;  53 263-268
    PubMedSuche in Google Scholar
  • 38 Brivio F, Brivio O, Lissoni P, Emanuelli G, Girlando M, Uggeri F. Presurgical neuroimmunotherapy with melatonin and interleukin-2 in cancer patients. In: Maestroni GJM, Conti A, Reiter RJ (Hrsg.). Therapeutic potential of melatonin. Front Horm Res. Basel: Karger 1997: 137-148
    Suche in Google Scholar
  • 39 Masotti A, Morandini G, Ortolani R, Fumagalli L. Phase-II randomized study of preoperative IL-2 administration in operable NSCLC.  Lung Cancer. 1998;  20 191-202
    CrossrefPubMedSuche in Google Scholar
  • 40 De Maeyer E, De Maeyer-Guignard J. Type I interferons. In: Bona CA, Revillard J-P (Hrsg.). Cytokines and cytokine receptors: physiology and pathological disorders. Amsterdam: Harwood Academic Publishers 2000: 316-333
    Suche in Google Scholar
  • 41 Luft T, Pang K C, Thomas E, Hertzog P, Hart D N, Trapani J, Cebon J. Type I IFNs enhance the terminal differentiation of dendritic cells.  J Immunol. 1998;  161 1947-1953
    PubMedSuche in Google Scholar
  • 42 Sedman P C, Ramsden C W, Brennan T G, Giles G R, Guillou P J. Effects of low dose perioperative interferon on the surgically induced suppression of antitumour immune responses.  Br J Surg. 1988;  75 976-981
    PubMedSuche in Google Scholar
  • 43 Fujioka T, Yoshida N, Hasegawa M, Ishikura K, Suzuki Y, Kubo T. Interleukin-2 expanded tumor-infiltrating lymphocytes and their response to preoperative α-interferon in patients with renal cell carcinoma.  J Urol. 1994;  152 852-856
    PubMedSuche in Google Scholar
  • 44 Houvenaeghel G, Bladou F, Blache J L, Olive D, Monges D, Jacquemier J, Chaudet H, Delpero J R, Guerinel G. Tolerance and feasibility of perioperative treatment with interferon-α2a in advanced cancers.  Int Surg. 1997;  82 165-169
    PubMedSuche in Google Scholar
  • 45 Sejima T, Miyagawa I. The evaluation of Fas/Fas ligand system in renal cell carcinoma - the effect of preoperative interferon-α therapy.  Nippon Hinyokika Gakkai Zasshi. 1999;  90 826-832
    PubMedSuche in Google Scholar
  • 46 Nielsen H J, Pedersen B K, Moesgaard F, Haahr P M, Kehlet H. Effect of ranitidine on postoperative suppression of natural killer cell activity and delayed hypersensitivity.  Acta Chir Scand. 1989;  155 377-382
    PubMedSuche in Google Scholar
  • 47 Katoh J, Tsuchiya K, Osawa H, Sato W, Matsumura G, Iida Y, Suzuki S, Hosaka S, Yoshii S, Tada Y. Cimetidine reduces impairment of cellular immunity after cardiac operations with cardiopulmonary bypass.  J Thorac Cardiovasc Surg. 1998;  116 312-318
    PubMedSuche in Google Scholar
  • 48 O'Riordain M G, Fearon K C, Ross J A, Rogers P, Falconer J S, Bartolo D C, Garden O J, Carter D C. Glutamine-supplemented total parenteral nutrition enhances T-lymphocyte response in surgical patients undergoing colorectal resection.  Ann Surg. 1994;  220 212-221
    PubMedSuche in Google Scholar
  • 49 Kerrebijn J D, Simons P J, Balm A J, Tas M, Knegt P P, de Vries N, Tan I B, Drexhage H A. Thymostimulin enhancement of T-cell infiltration into head and neck squamous cell carcinoma.  Head Neck. 1996;  18 335-342
    CrossrefPubMedSuche in Google Scholar
  • 50 Hamano K, Gohra H, Katoh T, Fujimura Y, Zempo N, Esato K. The preoperative administration of lentinan ameliorated the impairment of natural killer activity after cardiopulmonary bypass.  Int J Immunopharmacol. 1999;  21 531-540
    CrossrefPubMedSuche in Google Scholar
  • 51 Hubel K, Mansmann G, Schafer H, Oberhauser F, Diehl V, Engert A. Increase of antiinflammatory cytokines in patients with esophageal cancer after perioperative treatment with G-CSF.  Cytokine. 2000;  12 1797-1800
    CrossrefPubMedSuche in Google Scholar
  • 52 Bex A, Horenblas S, Meinhardt W, Verra N, de Gast G C. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ.  Eur Urol. 2002;  42 570-576
    CrossrefPubMedSuche in Google Scholar
  • 53 Morris K T, Johnson N, Homer L, Walts D. A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites.  Am J Surg. 2000;  179 407-411
    CrossrefPubMedSuche in Google Scholar
  • 54 Oz M C, Whitworth G C, Liu E H. Complementary medicine in the surgical wards.  JAMA. 1998;  279 710-711
    CrossrefPubMedSuche in Google Scholar
  • 55 Fair W R. Back to the future - the role of complementary medicine in urology.  J Urol. 1999;  162 411-420
    CrossrefPubMedSuche in Google Scholar
  • 56 Bruss K, Salter C, Galán E. American Cancer Society's guide to complementary and alternative cancer methods. Atlanta: American Cancer Society 2000
    Suche in Google Scholar

PD Dr. med. Malte Böhm

Urologische Klinik · Otto-von-Guericke Universität

Leipziger Str. 44

39120 Magdeburg

Telefon: 0391-67-15036

Fax: 0391-67-15094

eMail: malte.boehm@medizin.uni-magdeburg.de